Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F.

J Clin Oncol. 2005 May 20;23(15):3502-8.

PMID:
15908660
2.
3.

Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?

Kabbinavar FF, Ellis LM.

Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S69-73. Review.

PMID:
15479482
4.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

5.

Incidence and management of bevacizumab-related toxicities in colorectal cancer.

Saif MW, Mehra R.

Expert Opin Drug Saf. 2006 Jul;5(4):553-66. Review.

PMID:
16774493
6.

Capecitabine plus oxaliplatin for the treatment of colorectal cancer.

Carrato A, Gallego-Plazas J, Guillén-Ponce C.

Expert Rev Anticancer Ther. 2008 Feb;8(2):161-74. doi: 10.1586/14737140.8.2.161. Review.

PMID:
18279056
7.

Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.

Penland SK, Goldberg RM.

Clin Colorectal Cancer. 2004 Oct;4 Suppl 2:S74-80. Review.

PMID:
15479483
8.

The future development of bevacizumab in colorectal cancer.

Díaz-Rubio E, Schmoll HJ.

Oncology. 2005;69 Suppl 3:34-45. Epub 2005 Nov 21. Review.

PMID:
16301834
9.

Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).

Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M.

Drugs R D. 2011;11(2):101-11. doi: 10.2165/11590440-000000000-00000. Review.

10.

Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.

Hwang JJ, Eisenberg SG, Marshall JL.

Oncology (Williston Park). 2003 Sep;17(9 Suppl 8):37-43. Review.

11.
12.

The role of bevacizumab as first-line therapy for colon cancer.

Marshall J.

Semin Oncol. 2005 Dec;32(6 Suppl 9):S43-7. Review.

PMID:
16399431
13.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
14.

Targeting vascular endothelial growth factor in colorectal cancer.

Berlin JD.

Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):13-5. Review.

15.

Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer.

Lyseng-Williamson KA, Robinson DM.

BioDrugs. 2006;20(3):193-5. Review.

PMID:
16724868
16.

[Chemotherapy].

Aiba K.

Gan To Kagaku Ryoho. 2004 May;31(5):706-11. Review. Japanese.

PMID:
15170977
17.
18.

Bevacizumab in the treatment of colorectal cancer.

Mulcahy MF, Benson AB 3rd.

Expert Opin Biol Ther. 2005 Jul;5(7):997-1005. Review.

PMID:
16018743
19.

[Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].

Medinger M, Steinbild S, Mross K.

Praxis (Bern 1994). 2004 Sep 29;93(40):1633-44. Review. German.

PMID:
15495753
20.

The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.

Tappenden P, Jones R, Paisley S, Carroll C.

Eur J Cancer. 2007 Nov;43(17):2487-94. Epub 2007 Oct 1. Review.

PMID:
17910914

Supplemental Content

Support Center